L
Locus Biosciences
A biotechnology company that develops CRISPR-engineered precision antibacterial products
About Locus Biosciences
Locus Biosciences operates in the biotechnology sector, focusing on the development of precision antibacterial products to treat infectious diseases and microbiome-related conditions. The company leverages CRISPR-Cas3 engineered bacteriophages, branded as crPhage™, to specifically target and eradicate harmful bacterial pathogens. Locus Biosciences serves clients in the healthcare and pharmaceutical industries, including partnerships with major pharmaceutical companies like Janssen Pharmaceuticals. The company operates in the global market, with a business model centered around the development, licensing, and commercialization of its proprietary technologies. Revenue is generated through licensing agreements, research collaborations, and potential future sales of approved therapeutic products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Morrisville, United States
- Employees
- 61
- Open positions
- None listed
- Dealroom signal
- 72.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Bacteria, Genetics and genomics, Microbiology, Crispr, Spinout, Genome Engineering, Biotech and Pharma, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jan 2026 | $3.3M | — | US National Institute of Allergy and Infectious Diseases | ↗ |
| GRANTOther financing | Jan 2024 | $24M | — | US Biomedical Advanced Research and Development Authority | ↗ |
Growth signals
Latest recorded traffic for Locus Biosciences is 4.5K monthly website visits, down 8.2% over the last three months. Locus Biosciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
CARB-X
US Biomedical Advanced Research and Development Authority
US National Institute of Allergy and Infectious Diseases
Series A5 investors entered at this stage
Tencent
North Carolina Biotechnology Center
Viking Global Investors
Artis Ventures
Johnson & Johnson Innovation
Series B and later1 investor entered at this stage
Hercules Capital
Other known investors1 additional known investor
North Carolina State University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Locus Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Locus Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.